CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
000078 Shenzhen Neptunus Bioengineering
- 2.27
- +0.02+0.89%
Market Closed Apr 30 15:00 CST
5.97BMarket Cap-4.92P/E (TTM)
2.30High2.24Low136.30KlotVolume2.24Open2.25Pre Close31.01MTurnover0.52%Turnover RatioLossP/E (Static)2.63BShares3.1952wk High3.29P/B5.96BFloat Cap2.0752wk Low2.48Limit Up2.63BShs Float14.30Historical High2.03Limit Down2.67%Amplitude0.40Historical Low--Dividend TTM2.27Avg Price60.78KlotAsk--Div YieldTTM100Lot Size72.73KlotBid
Shenzhen Neptunus Bioengineering News
Neptune Biology: 2024 Annual Report
Neptune Biotech: Report for the first quarter of 2025
Neptune Biology: 2024 Annual Report Summary
Shenzhen Neptunus Bioengineering (000078.SZ): In the first quarter, the Net income was 23.7158 million yuan, a year-on-year decrease of 44.38%.
Gelonghui, on April 28, reported that Shenzhen Neptunus Bioengineering (000078.SZ) announced its first quarter report, with revenue of 7.376 billion yuan, a year-on-year decrease of 8.81%. The net income attributable to shareholders of the listed company was 23.7158 million yuan, a year-on-year decrease of 44.38%, and the non-recurring net loss was 74.74 million yuan.
There's No Escaping Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Muted Revenues
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Shenzhen Neptunus Bioengineering (000078.SZ): NEP018 has received the drug clinical trial approval notification.
On March 10, Gelonghui reported that Shenzhen Neptunus Bioengineering (000078.SZ) announced that its wholly-owned subsidiary, Shenzhen Neptunus Pharmaceutical Technology Research Institute Co., Ltd. (referred to as "Neptunus Pharmaceutical Research Institute"), recently received the clinical trial approval notice for NEP018 tablets issued by the National Medical Products Administration. NEP018 tablets are a new type of small molecule kinase inhibitor targeting tumors, independently developed by the Neptunus Pharmaceutical Research Institute, with independent intellectual property rights. Comprehensive preclinical research has shown that NEP018 tablets have good selective inhibitory activity against the designed targets and demonstrate good inhibitory effects on gastrointestinal tumors.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Even After Rising 7.2% This Past Week, Shenzhen Neptunus Bioengineering (SZSE:000078) Shareholders Are Still Down 52% Over the Past Five Years
Neptune Biotech: 2024 Annual Results Forecast
Shenzhen Neptunus Bioengineering (000078.SZ): The company's current medical device business is approximately 10 billion yuan in size.
Gelonghui November 13th | Shenzhen Neptunus Bioengineering (000078.SZ) stated in investor relations that the medical device distribution business has a higher gross profit level compared to the pharmaceutical distribution business, with relatively minor influence from policies. Therefore, the medical devices business is one of the company's key development sectors, with the current medical device business size reaching about tens of billions. In the future, the company will expand the scale of medical device distribution and agency business, aiming to transition from market agents to entities with the right to represent foreign brands, by introducing advanced technology and high-quality products from foreign brands to further enhance the company's level and competitiveness in the medical device business.
Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Neptune Biotech: Report for the third quarter of 2024
shenzhen neptunus bioengineering (000078.SZ): the net income in the first three quarters was 46.2173 million yuan, a year-on-year decrease of 47.77%.
On October 30, Gelonghui│ Shenzhen Neptunus Bioengineering (000078.SZ) released the third quarter report for 2024, with the company achieving revenue of 24.553 billion yuan in the first three quarters, a year-on-year decrease of 14.27%; net income attributable to shareholders of the listed company was 46.2173 million yuan, a year-on-year decrease of 47.77%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 19.7353 million yuan, a year-on-year decrease of 53.72%; basic earnings per share were 0.0176 yuan.
Investors in Shenzhen Neptunus Bioengineering (SZSE:000078) From Five Years Ago Are Still Down 18%, Even After 13% Gain This Past Week
Neptune Biotech: 2024 Semi-Annual Report Summary
Neptune Biology: 2024 Semi-Annual Report
Shenzhen Neptunus Bioengineering (000078.SZ): the net income in the first half of the year was 45.4098 million yuan, a decrease of 48.21% year-on-year.
Shenzhen Neptunus Bioengineering (000078.SZ) announced its semi-annual report for 2024, with a total operating income of 16.631 billion yuan, a decrease of 16.65% year-on-year; net income attributable to shareholders of the listed company was 45.4098 million yuan, a decrease of 48.21% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 38.9017 million yuan, a decrease of 28.11% year-on-year; basic earnings per share was 0.0173 yuan.
Express News | Neptunus Bioengineering Says Guangdong Provincial Government Will Be Co's Controlling Shareholder After the Deal
Express News | Neptunus Bioengineering Says Key Shareholder Shenzhen Neptunes Group Plans Sale of Stake to a Unit of Guangdong Provincial Government